An A-Mansia Biotech Food Supplement Could Help Manage Obesity, Diabetes and More
Obesity has become a global problem, posing the threat of type 2 diabetes and heart disease. A food supplement from The Akkermansia Company, previously known as A-Mansia Biotech, could offer a potential solution. On average, more than half of the citizens of Europe are markedly overweight, while global obesity rates have increased dramatically. These figures are based on a measurement known as the body mass index (BMI), calculated by dividing the weight in kilograms by the square of the height in metres. Subjects with a BMI equal to or greater than 25 are classified as clinically obese.
The underlying cause of this worrying trend is the 21st-century lifestyle. In short, this epidemic of obesity results from a diet of highly processed, sugary food and drinks and insufficient physical activity. Many of those who fall into this category will have been told by a doctor to adopt a healthier diet and exercise more. Sadly, many people who take this advice find that physical signs of weight loss do not happen overnight and may tend to revert to their previous lifestyles. In some cases, an improved diet and exercise regime are not capable of showing effective results quickly. Fortunately, thanks to a species of bacterium with promising properties, support is now available in the form of an innovative food supplement that can be taken in conjunction with a healthy diet and exercise regime.
A Novel Product from The Akkermansia Company (previously A-Mansia Biotech)
A-Mansia Biotech, rebranded as The Akkermansia Company refers to a startup operation based on discoveries made by two European scientists; Professor Willem de Vos of Wageningen University in the Netherlands and Professor Patrice Cani from Belgium’s UCLouvain. The former isolated a previously unknown species of bacterium from the human gut, and the two subsequently collaborated in studies that revealed a possible link between the new species, Akkermansia muciniphila, and several physiological activities, including inflammation control, the immune response, weight management and insulin sensitivity.
- muciniphila has since been shown to have probiotic properties. In 2019, it was approved by the European Food Safety Authority as “safe for human consumption in food supplements and foods for special medical purposes”.
Studies have shown that the numbers of A. muciniphila in the gut were markedly lower in obese subjects than in those with a normal BMI. Furthermore, other studies showed that correcting the deficiency with live and pasteurised cultures of this species led to weight loss, thus also limiting the various health risks commonly associated with obesity.
Benefits of The Akkermansia Company’s Award-nominated Food Supplement
In its pasteurised form, the species has several postbiotic effects, the most significant being its role in tackling gut barrier dysfunction that can lead to inflammatory conditions like irritable bowel syndrome, excess fat deposits in the liver, and lowered insulin sensitivity which can result in type 2 diabetes.
This unique microorganism forms the basis of a novel food supplement that, combined with EGCG green tea, chromium, and riboflavin (vitamin B2), has some invaluable health benefits. These include anti-inflammatory properties, weight management* and glucose control**.
If you are one of the many millions now struggling with obesity and related health problems or would like to be proactive in maintaining your health, click here to learn more about this innovative food supplement.